Secondary analysis of FLAURA2 patient-reported outcomes in EGFR-mutated advanced NSCLC: osimertinib with or without platinum-pemetrexed had no clinically meaningful effect on HRQoL; cough improved meaningfully in both arms.
Secondary analysis
Gray et al. Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer